omalizumab   Click here for help

GtoPdb Ligand ID: 6890

Synonyms: IGE25 | olizumab | R03DX05 | RG-3648 | rhumab-E25 | Xolair®
Approved drug Immunopharmacology Ligand
omalizumab is an approved drug (FDA (2003), EMA (2005))
Compound class: Antibody
Comment: Omalizumab is an anti-IgE monoclonal antibody that was desigend to target IgE-mediated allergic inflammatory responses.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that omalizumab is clone e25 in patent US5994511 [8].

Biosimilars:
The EMA approved Celltrion's biosimilar Omlyclo® in May 2024, to treat allergic asthma, chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria in patients for whom other therapy options have failed to control symptoms.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: omalizumab

References
1. Abdel-Gadir A, Schneider L, Casini A, Charbonnier LM, Little SV, Harrington T, Umetsu DT, Rachid R, Chatila TA. (2018)
Oral immunotherapy with omalizumab reverses the Th2 cell-like programme of regulatory T cells and restores their function.
Clin Exp Allergy, 48 (7): 825-836. [PMID:29700872]
2. An SB, Yang BG, Jang G, Kim DY, Kim J, Oh SM, Oh N, Lee S, Moon JY, Kim JA et al.. (2022)
Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy.
Nat Commun, 13 (1): 5669. [PMID:36167830]
3. Arm JP, Bottoli I, Skerjanec A, Floch D, Groenewegen A, Maahs S, Owen CE, Jones I, Lowe PJ. (2014)
Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects.
Clin Exp Allergy, 44 (11): 1371-85. [PMID:25200415]
4. Asero R. (2017)
Disappearance of severe oral allergy syndrome following omalizumab treatment.
Eur Ann Allergy Clin Immunol, 49 (3): 143-144. [PMID:28497679]
5. Bedoret D, Singh AK, Shaw V, Hoyte EG, Hamilton R, DeKruyff RH, Schneider LC, Nadeau KC, Umetsu DT. (2012)
Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab.
Mucosal Immunol, 5 (3): 267-76. [PMID:22318492]
6. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. (2001)
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
J Allergy Clin Immunol, 108 (2): 184-90. [PMID:11496232]
7. Lieberman JA, Chehade M. (2013)
Use of omalizumab in the treatment of food allergy and anaphylaxis.
Curr Allergy Asthma Rep, 13 (1): 78-84. [PMID:23065311]
8. Lowman HB, Presta LG, Jardieu PM, Lowe J. (1999)
Anti-IgE antibodies and methods of improving polypeptides.
Patent number: US5994511. Assignee: Genentech, Inc.. Priority date: 02/07/1997. Publication date: 30/11/1999.
9. Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM et al.. (2024)
Omalizumab for the Treatment of Multiple Food Allergies.
N Engl J Med, 390 (10): 889-899. [PMID:38407394]